Literature DB >> 18814609

Infection following hip replacement: solution options.

Fares S Haddad1, Anna Bridgens.   

Abstract

The key to the optimal management of an acutely infected arthroplasty is an expeditious diagnosis with careful assessment of the mode of presentation and treatment variables to determine the appropriate management strategy. At our institution acute infection is managed early and aggressively with debridement and exchange of mobile parts and change of the implant if it is cementless. For established chronic infection, each case is considered individually, using single-stage exchange in selected circumstances (1 in 6 cases). Two-stage exchange with an articulating spacer is used in the remainder. Single-stage revision offers clinical and economic advantages over a two-stage revision in selected patients, and although ongoing evaluation is still in place, currently we have had no reinfections in our single-stage revision cohort.

Entities:  

Mesh:

Year:  2008        PMID: 18814609     DOI: 10.3928/01477447-20080901-14

Source DB:  PubMed          Journal:  Orthopedics        ISSN: 0147-7447            Impact factor:   1.390


  4 in total

Review 1.  [Revision strategy for periprosthetic infection].

Authors:  B Lehner; D Witte; A J Suda; S Weiss
Journal:  Orthopade       Date:  2009-08       Impact factor: 1.087

2.  Application of temporarily functional antibiotic-containing bone cement prosthesis in revision hip arthroplasty.

Authors:  Ke Liu; Jia Zheng; Yi Jin; Yong-Qiang Zhao
Journal:  Eur J Orthop Surg Traumatol       Date:  2012-11-23

Review 3.  One-stage Exchange Arthroplasty for Periprosthetic Hip and Knee Joint Infections.

Authors:  Manny Nguyen; Mohamed Sukeik; Akos Zahar; Ikram Nizam; Fares Sami Haddad
Journal:  Open Orthop J       Date:  2016-11-30

Review 4.  Two-stage procedure in the treatment of late chronic hip infections--spacer implantation.

Authors:  Mohamed Sukeik; Fares S Haddad
Journal:  Int J Med Sci       Date:  2009-09-02       Impact factor: 3.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.